Download PDF
Kardiologie up2date 2024; 20(01): 65-76
DOI: 10.1055/a-2129-5915
Thrombozyten und Gerinnungssystem

Antithrombotische Therapiestrategien in der Atherosklerose

Martin Moser
,
Dirk Westermann
› Further Information
Also available at
    Permissions and Reprints All articles of this category

Atherosklerose und ihre Folgen stellen eine wichtige Krankheits- und Todesursache weltweit dar. Je nach Stadium und Risikoprofil der Erkrankung sind daher differenzierte antithrombotische Strategien erforderlich. Ob es sich um Primärprävention oder chronische Atherosklerose handelt – für jeden Patienten muss eine Therapiestrategie gefunden werden, für die eine individuelle Nutzen-Risiko-Abwägung unerlässlich ist.
Kernaussagen

  • Zur Prävention und Therapie der Atherosklerose gehört eine differenzierte antithrombotische Herangehensweise.

  • Im chronischen Stadium ist eine plättchenfunktionshemmende Monotherapie ausreichend.

  • Nach akuten Ischämien oder Gefäßinterventionen wird eine doppelte Plättchenaggregationshemmung (DAPT) notwendig, deren Dauer von den Begleitumständen abhängt.

  • Die Verlängerung oder Intensivierung der DAPT führt zwar zu einer Verschiebung des Verhältnisses von ischämischen gegenüber Blutungsendpunkten, die Sterblichkeit bleibt aber unverändert.

  • Die differenzierte Kombinationstherapie aus Plättchenfunktionshemmung und Hemmung der Gerinnungskaskade (DAT) ist in unterschiedlichen Dosierungen entsprechend den jeweiligen klinischen Konstellationen möglich.

  • Die niedrigdosierte DAT kommt für Patienten in arteriellen Hochrisikosituationen infrage.

  • Die Volldosis-DAT ist dagegen Therapie der Wahl für die ersten 6–12 Monate bei Patienten mit Indikation zur therapeutischen Gerinnungshemmung und zusätzlichen arteriellen Ereignissen wie PCI – ASS ist dann nur noch unmittelbar periinterventionell erforderlich.

Schlüsselwörter

Atherosklerose - antithrombotische Therapie - Plättchenfunktionshemmung - Antikoagulation


Publication History

Article published online:
18 March 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Baigent C, Blackwell L, Collins R. Antithrombotic Trialists’ (ATT) Collaboration. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860
    CrossrefPubMedSearch in Google Scholar
  • 2 McNeil JJ, Nelson MR, Woods RL. et al. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med 2018; 379: 1519-1528
    CrossrefPubMedSearch in Google Scholar
  • 3 Gaziano JM, Brotons C, Coppolecchia R. et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018; 392: 1036-1046
    CrossrefPubMedSearch in Google Scholar
  • 4 Group ASC, Bowman L, Mafham M. et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med 2018; 379: 1529-1539
    CrossrefPubMedSearch in Google Scholar
  • 5 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-1339
    CrossrefPubMedSearch in Google Scholar
  • 6 Gragnano F, Cao D, Pirondini L. et al. P2Y(12) Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events. J Am Coll Cardiol 2023; 82: 89-105
    CrossrefPubMedSearch in Google Scholar
  • 7 Byrne RA, Rossello X, Coughlan JJ. et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2023; 44: 3720-3826
    CrossrefPubMedSearch in Google Scholar
  • 8 Schomig A, Neumann FJ, Kastrati A. et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-1089
    CrossrefPubMedSearch in Google Scholar
  • 9 Valgimigli M, Bueno H, Byrne RA. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39: 213-260
    CrossrefPubMedSearch in Google Scholar
  • 10 Gragnano F, Mehran R, Branca M. et al. P2Y(12) Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions. J Am Coll Cardiol 2023; 81: 537-552
    CrossrefPubMedSearch in Google Scholar
  • 11 Watanabe H, Domei T, Morimoto T. et al. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA 2019; 321: 2414-2427
    CrossrefPubMedSearch in Google Scholar
  • 12 Jernberg T, Hasvold P, Henriksson M. et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 2015; 36: 1163-1170
    CrossrefPubMedSearch in Google Scholar
  • 13 Mauri L, Kereiakes DJ, Yeh RW. et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155-2166
    CrossrefPubMedSearch in Google Scholar
  • 14 Alexander JH, Lopes RD, James S. et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365: 699-708
    CrossrefPubMedSearch in Google Scholar
  • 15 Oldgren J, Budaj A, Granger CB. et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32: 2781-2789
    CrossrefPubMedSearch in Google Scholar
  • 16 Mega JL, Braunwald E, Mohanavelu S. et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009; 374: 29-38
    CrossrefPubMedSearch in Google Scholar
  • 17 Mega JL, Braunwald E, Wiviott SD. et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19
    CrossrefPubMedSearch in Google Scholar
  • 18 Eikelboom JW, Connolly SJ, Bosch J. et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017; 377: 1319-1330
    CrossrefPubMedSearch in Google Scholar
  • 19 Bonaca MP, Bauersachs RM, Anand SS. et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med 2020; 382: 1994-2004
    CrossrefPubMedSearch in Google Scholar
  • 20 Angiolillo DJ, Galli M, Collet JP. et al. Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention 2022; 17: e1371-e1396
    CrossrefPubMedSearch in Google Scholar
  • 21 Connolly S, Pogue J, Hart R. ACTIVE Writing Group of the ACTIVE Investigators. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-1912
    CrossrefPubMedSearch in Google Scholar
  • 22 Gao F, Zhou YJ, Wang ZJ. et al. Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation. Circ J 2010; 74: 701-708
    CrossrefPubMedSearch in Google Scholar
  • 23 Gibson CM, Mehran R, Bode C. et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016; 375: 2423-2434
    CrossrefPubMedSearch in Google Scholar
  • 24 Cannon CP, Bhatt DL, Oldgren J. et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med 2017; 377: 1513-1524
    CrossrefPubMedSearch in Google Scholar
  • 25 Lopes RD, Heizer G, Aronson R. et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med 2019; 380: 1509-1524
    CrossrefPubMedSearch in Google Scholar
  • 26 Vranckx P, Valgimigli M, Eckardt L. et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet 2019; 394: 1335-1343
    CrossrefPubMedSearch in Google Scholar
  • 27 Galli M, Andreotti F, Porto I. et al. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients. Europace 2020; 22: 538-546
    CrossrefPubMedSearch in Google Scholar
  • 28 Kumbhani DJ, Cannon CP, Beavers CJ. et al. 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2021; 77: 629-658
    CrossrefPubMedSearch in Google Scholar
  • 29 Lip GYH, Collet JP, Haude M. et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace 2019; 21: 192-193
    CrossrefPubMedSearch in Google Scholar